207 related articles for article (PubMed ID: 35971323)
21. Progesterone receptor modulators for endometriosis.
Fu J; Song H; Zhou M; Zhu H; Wang Y; Chen H; Huang W
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009881. PubMed ID: 28742263
[TBL] [Abstract][Full Text] [Related]
22. Emerging drugs for endometriosis.
Fedele L; Berlanda N
Expert Opin Emerg Drugs; 2004 May; 9(1):167-77. PubMed ID: 15155142
[TBL] [Abstract][Full Text] [Related]
23. An Evidence-Based Review of Elagolix for the Treatment of Pain Secondary to Endometriosis.
Urits I; Adamian L; Miro P; Callan J; Patel PM; Patel M; Berger AA; Kassem H; Kaye AD; Viswanath O
Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):197-215. PubMed ID: 33633426
[TBL] [Abstract][Full Text] [Related]
24. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
[TBL] [Abstract][Full Text] [Related]
25. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence.
Jensen JT; Schlaff W; Gordon K
Fertil Steril; 2018 Jul; 110(1):137-152.e1. PubMed ID: 29937152
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of endometriosis by aromatase inhibitors: efficacy and side effects].
Racine AC; Legrand E; Lefebvre-Lacoeuille C; Hoppe E; Catala L; Sentilhes L; Descamps P
Gynecol Obstet Fertil; 2010 May; 38(5):318-23. PubMed ID: 20430665
[TBL] [Abstract][Full Text] [Related]
27. Medical treatments for endometriosis-associated pelvic pain.
Zito G; Luppi S; Giolo E; Martinelli M; Venturin I; Di Lorenzo G; Ricci G
Biomed Res Int; 2014; 2014():191967. PubMed ID: 25165691
[TBL] [Abstract][Full Text] [Related]
28. Current and Emerging Therapeutics for the Management of Endometriosis.
Ferrero S; Barra F; Leone Roberti Maggiore U
Drugs; 2018 Jul; 78(10):995-1012. PubMed ID: 29946962
[TBL] [Abstract][Full Text] [Related]
29. Chinese herbal medicine for endometriosis.
Flower A; Liu JP; Lewith G; Little P; Li Q
Cochrane Database Syst Rev; 2012 May; (5):CD006568. PubMed ID: 22592712
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
31. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
32. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
33. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
34. Medical management of endometriosis: a systematic review.
Schroder AK; Diedrich K; Ludwig M
IDrugs; 2004 May; 7(5):451-63. PubMed ID: 15154107
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
Taylor HS; Dun EC; Chwalisz K
Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
[TBL] [Abstract][Full Text] [Related]
36. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
[TBL] [Abstract][Full Text] [Related]
37. A review of phase II and III drugs for the treatment and management of endometriosis.
Perrone U; Evangelisti G; Laganà AS; Bogliolo S; Ceccaroni M; Izzotti A; Gustavino C; Ferrero S; Barra F
Expert Opin Emerg Drugs; 2023 Dec; 28(4):333-351. PubMed ID: 38099328
[TBL] [Abstract][Full Text] [Related]
38. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
Ezzati M; Carr BR
Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
[TBL] [Abstract][Full Text] [Related]
39. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
40. Endometriosis: alternative methods of medical treatment.
Muñoz-Hernando L; Muñoz-Gonzalez JL; Marqueta-Marques L; Alvarez-Conejo C; Tejerizo-García Á; Lopez-Gonzalez G; Villegas-Muñoz E; Martin-Jimenez A; Jiménez-López JS
Int J Womens Health; 2015; 7():595-603. PubMed ID: 26089705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
